Cargando…

Combining pretreatment plasma Epstein‐Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study

This study aimed to evaluate the prognostic value of combining pretreatment Epstein‐Barr virus (EBV) DNA level and cervical node necrosis (CNN) for patients with nasopharyngeal carcinoma (NPC) receiving intensity‐modulated radiotherapy (IMRT). A total of 607 incident nonmetastatic NPC patients treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Yu‐Yun, Luo, Dong‐Hua, Sun, Xue‐Song, Tang, Lin‐Quan, Mai, Hai‐Qiang, Chen, Qiu‐Yan, Zhong, Jing‐Hua, Mai, Dong‐Mei, Zhang, Wan‐Ru, Chen, Wen‐Hui, Mo, Hao‐Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853822/ https://www.ncbi.nlm.nih.gov/pubmed/31513364 http://dx.doi.org/10.1002/cam4.2481

Ejemplares similares

Identifying optimal candidates for induction chemotherapy among stage II–IVa nasopharyngeal carcinoma based on pretreatment Epstein–Barr virus DNA and nodal maximal standard uptake values of [(18)F]‐fluorodeoxyglucose positron emission tomography
por: Xie, Hao‐Jun, et al.
Publicado: (2020)

Individualized concurrent chemotherapy by pretreatment plasma Epstein‐Barr viral DNA in II‐III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort
por: Sun, Xue‐Song, et al.
Publicado: (2019)

Relationship between pretreatment concentration of plasma Epstein‐Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation
por: Peng, Liang, et al.
Publicado: (2018)

Plasma Epstein–Barr Viral Deoxyribonucleic Acid Predicts Worse Outcomes in Pediatric Nonmetastatic Nasopharyngeal Carcinoma Patients: An Observational Study of 89 Cases in an Endemic Area
por: Shen, Ting, et al.
Publicado: (2015)

Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity‐modulated radiotherapy: A large‐scale retrospective study
por: Zhang, Lu‐Lu, et al.
Publicado: (2017)

Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study
por: Chen, Qiu-Yan, et al.
Publicado: (2018)

Associations between environmental factors and serological Epstein‐Barr virus antibodies in patients with nasopharyngeal carcinoma in South China
por: Zhou, Ting, et al.
Publicado: (2019)

Mechanisms of Epstein‐Barr virus nuclear antigen 1 favor Tregs accumulation in nasopharyngeal carcinoma
por: Wang, Jie, et al.
Publicado: (2020)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

Different Prognostic Values of Plasma Epstein-Barr Virus DNA and Maximal Standardized Uptake Value of (18)F-FDG PET/CT for Nasopharyngeal Carcinoma Patients with Recurrence
por: Shen, Ting, et al.
Publicado: (2015)

Decreased oral Epstein‐Barr virus DNA loads in patients with nasopharyngeal carcinoma in Southern China: A case‐control and a family‐based study
por: Xue, Wen‐Qiong, et al.
Publicado: (2018)

Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein‐Barr virus associated nasopharyngeal carcinoma
por: Liu, Lingzhi, et al.
Publicado: (2019)

Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study
por: Chen, Qiu-Yan, et al.
Publicado: (2018)

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein–Barr virus DNA level after induction chemotherapy
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Roles of Inflammasomes in Epstein–Barr Virus-Associated Nasopharyngeal Cancer
por: Looi, Chin King, et al.
Publicado: (2021)

Evaluation of plasma Epstein–Barr virus DNA as a biomarker for Epstein–Barr virus–associated Hodgkin lymphoma
por: Usha, Masuma Khatun, et al.
Publicado: (2021)

Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma
por: Li, Xiaoyu, et al.
Publicado: (2022)

Response to the hunt for the perfect biomarker in nasopharyngeal carcinoma—the RRAS “race” beyond Epstein-barr virus?
por: Xiao, Ruowen, et al.
Publicado: (2019)

Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein‐Barr Virus: An analysis of a prospective study in southern China
por: Hu, Ting, et al.
Publicado: (2019)

Prognostic value of MRI‐determined cervical lymph node size in nasopharyngeal carcinoma
por: Huang, Cheng‐Long, et al.
Publicado: (2020)

The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma
por: Li, You Quan, et al.
Publicado: (2018)

Epstein-Barr virus and nasopharyngeal carcinoma
por: Young, Lawrence S., et al.
Publicado: (2014)

The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study
por: Liu, Sai-Lan, et al.
Publicado: (2019)

Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2016)

Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
por: Zhang, Wan-Ru, et al.
Publicado: (2021)

Biopsy of cervical lymph node does not impact the survival of nasopharyngeal carcinoma
por: Yang, Shi‐Ping, et al.
Publicado: (2021)

Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein‐Barr virus capsid antigen: A mediation analysis
por: Hsu, Wan‐Lun, et al.
Publicado: (2020)

Characterization of Epstein-Barr Virus miRNAome in Nasopharyngeal Carcinoma by Deep Sequencing
por: Chen, Shu-Jen, et al.
Publicado: (2010)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Epstein–Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma
por: Xia, Bing, et al.
Publicado: (2019)

Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma
por: Liu, Ming‐Zhu, et al.
Publicado: (2019)

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
por: Hau, Pok Man, et al.
Publicado: (2020)

The role of Epstein–Barr virus in nasopharyngeal carcinoma
por: Su, Zhi Yi, et al.
Publicado: (2023)

Dynamic changes in plasma Epstein–Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study
por: He, Sha‐Sha, et al.
Publicado: (2018)

Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma
por: Lin, Cheng, et al.
Publicado: (2022)

Clinical findings and imaging features of 67 nasopharyngeal carcinoma patients with postradiation nasopharyngeal necrosis
por: Chen, Ming-Yuan, et al.
Publicado: (2013)

Recurrence risk stratification based on Epstein–Barr virus DNA to identify enlarged retropharyngeal lymph nodes of nasopharyngeal carcinoma: A model-histopathologic correlation study
por: Mao, Minjie, et al.
Publicado: (2022)

Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population
por: Chen, Wen-Jie, et al.
Publicado: (2021)

The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA
por: Jin, Ya-Nan, et al.
Publicado: (2017)

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells
por: Kawada, Jun‐ichi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_374e8a3vkkb26jg04389qm9dof